A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yield the hoped-for dose-response data, ...

Python stays far ahead after another dip; C holds second, Java retakes third from C++, and R rises to eighth as SQL slips, ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

The Mojo language is finally available in a 1.0 release. It’s billed as “write like Python, run like C++”, and it offers compatibility with the Python ecosystem along with many memory safety metaphors ...

A new study has uncovered why some brain cells are more resistant to Alzheimer’s damage than others. Researchers found a natural cleanup system that helps remove toxic tau protein before it can form ...

Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...